Zoetis Inc. (NYSE:ZTS) is one of the best drug stocks to buy right now. Zoetis Inc. (NYSE:ZTS) announced on September 12 the adoption of a positive opinion by the Committee for Veterinary Medicinal Products (CVMP) of the European Medicines Agency (EMA) regarding recommending the granting of marketing authorization for Portela (relfovetmab). Is Zoetis a Unique Dividend Play in the Pharma Space for 2025? Portela is a new monoclonal antibody (mAb) therapy intended to alleviate pain associated with osteoarth ...

Key Takeaways Zoetis gained CVMP support for Portela, a monoclonal antibody for feline OA pain relief.Portela offers up to 3 months of pain relief with one jab and was well-tolerated in clinical studies.Portela will complement Solensia, giving vets and owners both monthly and quarterly OA pain therapy options.Zoetis (ZTS) announced that the European Medicines Agency’s Committee for Veterinary Medicinal Products (CVMP) has issued a positive opinion for its investigational monoclonal antibody (mAb) therapy, P ...

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--If approved, Zoetis' Portela will be the first long-acting anti-NGF mAb therapy for cats and is designed to provide 3 months of OA pain relief. ...

Zoetis Inc. (NYSE:ZTS) is one of the 11 Best Roth IRA Stocks to Invest in Now. Zoetis Inc. (ZTS) Secures a New Five-Year $1.25 Billion Senior Unsecured Revolving Credit Facility Zoetis Inc. (NYSE:ZTS) strengthened its financial flexibility on August 27, 2025, by securing a new five-year, $1.25 billion senior unsecured revolving credit facility. The agreement replaces a 2022 facility that would have expired in 2027. The agreement was administered by JPMorgan Chase, while Barclays, Bank of America, Citiban ...

Zoetis Inc. (NYSE:ZTS) has shown resilience with a slight increase of 0.013% over the past month, despite a recent dip of 3.23% in the last 10 days.The company boasts a projected stock price increase of 21.28%, highlighting its significant growth potential and strong market position.Zoetis's financial health is solid, with a Piotroski Score of 8, indicating strong financial stability and operational efficiency.Zoetis Inc. (NYSE:ZTS) is a leading global animal health company, dedicated to the discovery, deve ...

股价表现 - 公司股价收于14979美元 单日下跌129% 表现落后于标普500指数027%的涨幅 道琼斯指数上涨043% 纳斯达克指数上涨037% [1] - 近一个月股价累计上涨183% 表现不及医疗行业654%的涨幅 且略微落后标普500指数185%的涨幅 [1] 财务预期 - 预计季度每股收益164美元 同比增长38% 季度营收预计243亿美元 同比增长156% [2] - 全年每股收益预期634美元 同比增长709% 全年营收预期951亿美元 同比增长279% [3] 估值水平 - 公司远期市盈率为2394倍 较行业平均1552倍存在溢价 [6] - 市盈增长比率为244倍 显著高于医疗药物行业平均155倍的水平 [6] 分析师评级 - 过去一个月共识每股收益预期上调008% 目前获得Zacks第三级持有评级 [5] - 医疗药物行业在Zacks行业排名中位列第87位 处于所有250多个行业的前36%分位 [7] 业绩预测调整 - 分析师预估调整反映短期业务趋势变化 正面修正通常预示积极业务前景 [3] - 预估修正与短期股价波动存在直接关联 Zacks评级系统基于这些变化提供操作建议 [4]

PresentationErin Wilson WrightEquity Analyst Good afternoon, everyone. Welcome to the Morgan Stanley Healthcare Conference. I'm Erin Wright, Healthcare Services analyst for more important disclosures, please see the Morgan Stanley research disclosure website at morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative. With that, we're happy to have Zoetis with us today. So thank you. We have CEO, Kristin Peck, as well as CFO, Wetteny Jose ...

Zoetis (NYSE:ZTS) FY Conference September 08, 2025 01:05 PM ET Unknown Speakertextnumber_of_speakersparagraphs ...

作者背景 - 作者拥有电子与通信工程学士学位、计算机科学硕士学位、商业管理研究生学位以及计算机应用博士学位 [1] - 作者与另一位分析师在Seeking Alpha平台独立进行专业分析并遵守平台共享准则 [1] 披露声明 - 作者未持有任何提及公司的股票、期权或衍生品头寸 且72小时内无相关计划 [2] - 文章为作者独立完成 未获得除Seeking Alpha外任何形式的报酬 [2] - 作者与提及股票的公司不存在业务关联关系 [2] 平台性质说明 - Seeking Alpha平台分析师包含专业投资者与个人投资者 未全部经过机构或监管机构认证 [3] - 平台观点不代表整体立场 且不提供投资建议或证券交易服务 [3]

公司业务与市场地位 - 硕腾公司是全球宠物和牲畜健康产品市场的领导者 拥有卓越的增长前景和业务展望 [1] - 公司具有极其稳固的股息安全性 并系统性地向股东返还现金 [1] 投资策略与关注重点 - 投资策略侧重于股息增长型投资 着眼于长期投资视野 并相信股息增长投资的复利效应 [1] - 通常寻找具有可持续股息增长和资本增值潜力的大型低估股票 [1] - 次要关注点是有增长潜力的科技股及中小型股票 不论是否派发股息 [1]